Home ETF List About

Portfolio Holdings Detail for ISIN IE0031442068
Stock Name / FundiShares Core S&P 500 UCITS ETF USD (Dist)
IssuerBlackrock
Entity holding fund iShares Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300YDM1GFZR5B4U80
ETF TickerIDUS(USD) LSE
ETF TickerIDUS.LS(USD) CXE
ETF TickerIUSA.AS(EUR) CXE
ETF TickerIUSA.DE(EUR) CXE
ETF TickerIUSA.LS(GBX) CXE
ETF TickerIUSA.MI(EUR) CXE
ETF TickerIUSAz(USD) CXE
ETF TickerIUSA(EUR) ETF Plus
ETF TickerIDUS.L(GBP) LSE

Holdings detail for CRL

Stock NameCreightons Plc
TickerCRL(GBX) LSE
TYPECommon Stock
CountryUK
ISINGB0002341666
LEI213800WROWAJUBGSAJ57

Show aggregate CRL holdings

News associated with CRL

Charles River Laboratories International (NYSE:CRL) Downgraded to “Buy” Rating by Wall Street Zen
Wall Street Zen lowered shares of Charles River Laboratories International (NYSE:CRL – Free Report) from a strong-buy rating to a buy rating in a report issued on Sunday morning. Several other research firms also recently issued reports on CRL. Evercore ISI lifted their price target on Charles River Laboratories International from $180.00 to $190.00 and […] - 2025-09-22 03:13:04
Charles River CFO Flavia Pease To Step Down; Michael Knell Appointed Interim CFO
(RTTNews) - Charles River Laboratories International, Inc. (CRL) announced Tuesday that Flavia H. Pease, corporate executive vice president and chief financial officer, has resigned effective September 29, 2025, to pursue another opportunity. - 2025-09-16 08:28:15
Brokerages Set Charles River Laboratories International, Inc. (NYSE:CRL) PT at $175.69
Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) has received a consensus rating of “Hold” from the fifteen research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and five have given a buy recommendation to […] - 2025-08-29 04:49:03
Wall Street Zen Downgrades Charles River Laboratories International (NYSE:CRL) to Buy
Charles River Laboratories International (NYSE:CRL – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued to investors on Sunday. CRL has been the topic of a number of other reports. Robert W. Baird upped their price objective on Charles […] - 2025-08-19 02:50:57
Maryland State Retirement & Pension System Reduces Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)
Maryland State Retirement & Pension System lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 18.2% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,387 shares of the medical research company’s stock after […] - 2025-08-17 05:17:00
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Acquired by Charles Schwab Investment Management Inc.
Charles Schwab Investment Management Inc. boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 4.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 577,322 shares of the medical research company’s stock after purchasing an additional 24,347 […] - 2025-08-13 05:42:56
Federated Hermes Inc. Lowers Position in Charles River Laboratories International, Inc. (NYSE:CRL)
Federated Hermes Inc. cut its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 90.6% in the first quarter, Holdings Channel reports. The fund owned 225 shares of the medical research company’s stock after selling 2,172 shares during the quarter. Federated Hermes Inc.’s holdings in Charles River Laboratories International were worth $34,000 […] - 2025-08-12 05:06:53
Analysts Expect 10% Gains Ahead For The Holdings of SPUS
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-11 10:38:26
Kestra Private Wealth Services LLC Sells 115 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
Kestra Private Wealth Services LLC lowered its stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 5.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,929 shares of the medical research company’s stock after selling 115 […] - 2025-07-28 05:24:49
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Mutual of America Capital Management LLC
Mutual of America Capital Management LLC trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 2.9% in the first quarter, HoldingsChannel reports. The institutional investor owned 5,938 shares of the medical research company’s stock after selling 179 shares during the period. Mutual of America Capital Management LLC’s holdings […] - 2025-07-22 07:06:50
Arizona State Retirement System Sells 336 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
Arizona State Retirement System decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 2.2% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,659 shares of the medical research company’s stock after selling 336 shares during the quarter. Arizona […] - 2025-07-18 05:10:58
Nisa Investment Advisors LLC Decreases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)
Nisa Investment Advisors LLC reduced its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 23.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,737 shares of the medical research company’s stock after selling 1,417 shares during […] - 2025-07-16 05:44:56
Brown Advisory Inc. Has $334,000 Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)
Brown Advisory Inc. lowered its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 84.9% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,219 shares of the medical research company’s stock after selling 12,506 shares during the period. Brown Advisory […] - 2025-07-16 04:56:59
Teacher Retirement System of Texas Takes $1.23 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)
Teacher Retirement System of Texas acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) in the 1st quarter, Holdings Channel.com reports. The institutional investor acquired 8,180 shares of the medical research company’s stock, valued at approximately $1,231,000. Several other hedge funds also recently modified their holdings of the stock. Aaron […] - 2025-07-13 06:14:56
Charles River Laboratories International Reaches Analyst Target Price
In recent trading, shares of Charles River Laboratories International Inc. (Symbol: CRL) have crossed above the average analyst 12-month target price of $158.64, changing hands for $158.97/share. When a stock reaches the target an analyst has set, the analyst logically has two w - 2025-07-10 07:56:40
Charles River Laboratories International, Inc. (NYSE:CRL) Given Average Recommendation of “Hold” by Analysts
Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report) has received an average rating of “Hold” from the sixteen ratings firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation and four have assigned a buy recommendation to the company. […] - 2025-07-07 04:26:46
New York State Teachers Retirement System Sells 4,446 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
New York State Teachers Retirement System lessened its holdings in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 9.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 40,784 shares of the medical research company’s stock after selling 4,446 shares […] - 2025-07-06 07:56:57
Sequoia Financial Advisors LLC Has $264,000 Position in Charles River Laboratories International, Inc. (NYSE:CRL)
Sequoia Financial Advisors LLC reduced its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 10.6% in the first quarter, HoldingsChannel.com reports. The fund owned 1,755 shares of the medical research company’s stock after selling 207 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Charles River Laboratories International […] - 2025-07-04 04:45:03
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Wealth Enhancement Advisory Services LLC
Wealth Enhancement Advisory Services LLC trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 4.1% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,723 shares of the medical research company’s stock after selling 247 shares during the period. […] - 2025-07-03 04:26:50
Bessemer Group Inc. Sells 16,538 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
Bessemer Group Inc. trimmed its position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 70.5% during the first quarter, HoldingsChannel.com reports. The fund owned 6,935 shares of the medical research company’s stock after selling 16,538 shares during the quarter. Bessemer Group Inc.’s holdings in Charles River Laboratories International were worth $1,044,000 at […] - 2025-07-01 05:46:49
Asset Management One Co. Ltd. Sells 17,428 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
Asset Management One Co. Ltd. lessened its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 92.1% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,490 shares of the medical research company’s stock after selling 17,428 shares during the […] - 2025-07-01 04:54:50
Congress Trade: Representative Jefferson Shreve Just Disclosed New Stock Trades
Representative Jefferson Shreve just filed new stock trades, which we received from a STOCK Act disclosure. You can see the full list of trades on Quiver Quantitative's congress trading dashboard, and track the portfolios of Representative Jefferson Shreve and other politicians. - 2025-06-23 10:13:39
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Blue Trust Inc.
Blue Trust Inc. grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 60.1% in the 1st quarter, HoldingsChannel.com reports. The fund owned 2,407 shares of the medical research company’s stock after acquiring an additional 904 shares during the period. Blue Trust Inc.’s holdings in Charles River Laboratories International […] - 2025-06-23 06:18:50
Yousif Capital Management LLC Has $856,000 Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)
Yousif Capital Management LLC lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 3.6% in the first quarter, Holdings Channel.com reports. The firm owned 5,687 shares of the medical research company’s stock after selling 215 shares during the period. Yousif Capital Management LLC’s holdings in Charles River Laboratories […] - 2025-06-20 04:32:47
Tuesday Sector Laggards: Healthcare, Technology & Communications
The worst performing sector as of midday Tuesday is the Healthcare sector, showing a 1.4% loss. Within the sector, Charles River Laboratories International Inc. (Symbol: CRL) and Align Technology Inc (Symbol: ALGN) are two large stocks that are lagging, showing a loss of 4.4% an - 2025-06-17 15:32:11
Fifth Third Bancorp Lowers Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)
Fifth Third Bancorp lowered its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 18.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,747 shares of the medical research company’s stock after selling 2,030 shares during the […] - 2025-06-16 05:32:50
Handelsbanken Fonder AB Has $1.74 Million Stake in Charles River Laboratories International, Inc. (NYSE:CRL)
Handelsbanken Fonder AB reduced its position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 7.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,537 shares of the medical research company’s stock after selling 900 shares during the […] - 2025-06-15 06:40:51
Congress Asset Management Co. Sells 1,482 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)
Congress Asset Management Co. lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 34.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,879 shares of the medical research company’s stock after selling 1,482 shares during […] - 2025-06-10 05:04:52
Rhumbline Advisers Has $13.06 Million Stake in Charles River Laboratories International, Inc. (NYSE:CRL)
Rhumbline Advisers boosted its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 4.1% in the first quarter, HoldingsChannel reports. The firm owned 86,730 shares of the medical research company’s stock after acquiring an additional 3,405 shares during the period. Rhumbline Advisers’ holdings in Charles River Laboratories International were worth […] - 2025-06-09 06:02:56
Universal Beteiligungs und Servicegesellschaft mbH Invests $3.58 Million in Charles River Laboratories International, Inc. (NYSE:CRL)
Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 19,410 shares of the medical research company’s stock, valued at approximately $3,583,000. A number of other […] - 2025-06-02 05:58:52

iShares Core S&P 500 UCITS ETF USD (Dist) CRL holdings

DateNumber of CRL Shares HeldBase Market Value of CRL SharesLocal Market Value of CRL SharesChange in CRL Shares HeldChange in CRL Base ValueCurrent Price per CRL Share HeldPrevious Price per CRL Share Held
2025-09-29 (Monday)17,508USD 2,573,501CRL holding decreased by -27487USD 2,573,5010USD -27,487 USD 146.99 USD 148.56
2025-09-26 (Friday)17,508USD 2,600,988CRL holding increased by 52348USD 2,600,9880USD 52,348 USD 148.56 USD 145.57
2025-09-25 (Thursday)17,508CRL holding increased by 7USD 2,548,640CRL holding decreased by -66884USD 2,548,6407USD -66,884 USD 145.57 USD 149.45
2025-09-24 (Wednesday)17,501CRL holding decreased by -21USD 2,615,524CRL holding decreased by -135255USD 2,615,524-21USD -135,255 USD 149.45 USD 156.99
2025-09-18 (Thursday)17,522CRL holding increased by 7USD 2,750,779CRL holding increased by 75888USD 2,750,7797USD 75,888 USD 156.99 USD 152.72
2025-09-17 (Wednesday)17,515CRL holding increased by 7USD 2,674,891CRL holding increased by 20678USD 2,674,8917USD 20,678 USD 152.72 USD 151.6
2025-09-16 (Tuesday)17,508USD 2,654,213CRL holding decreased by -11205USD 2,654,2130USD -11,205 USD 151.6 USD 152.24
2025-09-15 (Monday)17,508USD 2,665,418USD 2,665,418
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of CRL by Blackrock for IE0031442068

Show aggregate share trades of CRL

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-25BUY7 145.570* 160.99
2025-09-24SELL-21 149.450* 161.04 Profit of 3,382 on sale
2025-09-18BUY7 156.990* 161.07
2025-09-17BUY7 152.720* 161.11
2025-08-19SELL-14 158.480* 161.21 Profit of 2,257 on sale
2025-08-15SELL-7 156.680* 161.26 Profit of 1,129 on sale
2025-08-13SELL-35 155.000* 161.29 Profit of 5,645 on sale
2025-08-12SELL-91 152.750* 161.33 Profit of 14,681 on sale
2025-08-07SELL-105 149.780* 161.39 Profit of 16,946 on sale
2025-08-05BUY7 167.490* 161.42
2025-07-31BUY21 169.640* 161.38
2025-07-28BUY7 178.990* 161.11
2025-07-25SELL-14 176.930* 161.02 Profit of 2,254 on sale
2025-07-22SELL-863 163.360* 160.97 Profit of 138,918 on sale
2025-07-18BUY7 154.480* 161.07
2025-07-14SELL-7 158.040* 161.18 Profit of 1,128 on sale
2025-07-08SELL-14 158.390* 161.20 Profit of 2,257 on sale
2025-07-02BUY42 157.490* 161.31
2025-06-24SELL-14 148.400* 161.64 Profit of 2,263 on sale
2025-06-23SELL-7 147.380* 161.73 Profit of 1,132 on sale
2025-06-20SELL-42 147.450* 161.82 Profit of 6,796 on sale
2025-06-12SELL-21 151.890* 162.20 Profit of 3,406 on sale
2025-06-06BUY7 144.700* 162.55
2025-06-02SELL-21 135.040* 163.17 Profit of 3,427 on sale
2025-05-29SELL-7 137.700* 163.53 Profit of 1,145 on sale
2025-05-27BUY7 138.650* 163.88
2025-05-23BUY7 136.730* 164.26
2025-05-21SELL-21 134.980* 164.67 Profit of 3,458 on sale
2025-05-15BUY28 138.890* 165.35
2025-05-14SELL-42 138.950* 165.54 Profit of 6,953 on sale
2025-05-13SELL-84 144.020* 165.70 Profit of 13,919 on sale
2025-05-07SELL-21 136.970* 166.48 Profit of 3,496 on sale
2025-05-02SELL-7 118.460* 167.61 Profit of 1,173 on sale
2025-04-29SELL-21 117.290* 168.80 Profit of 3,545 on sale
2025-04-24BUY7 115.760* 170.11
2025-04-22BUY28 106.890* 171.14
2025-04-16BUY7 104.250* 173.41
2025-04-15BUY7 105.920* 173.99
2025-04-11BUY14 99.750* 175.23
2025-04-09BUY35 139.070* 176.22
2025-04-08BUY105 123.610* 176.70
2025-04-07SELL-49 134.070* 177.09 Profit of 8,677 on sale
2025-04-04SELL-105 136.900* 177.45 Profit of 18,633 on sale
2025-04-02SELL-21 149.280* 177.72 Profit of 3,732 on sale
2025-04-01SELL-7 145.990* 178.01 Profit of 1,246 on sale
2025-03-31SELL-14 150.520* 178.27 Profit of 2,496 on sale
2025-03-28BUY14 155.550* 178.49
2025-03-25BUY21 161.350* 179.05
2025-03-24BUY28 166.980* 179.17
2025-03-21SELL-14 167.280* 179.29 Profit of 2,510 on sale
2025-03-20BUY14 165.350* 179.43
2025-03-19BUY28 173.880* 179.49
2025-03-17SELL-21 175.010* 179.56 Profit of 3,771 on sale
2025-03-14SELL-14 171.040* 179.65 Profit of 2,515 on sale
2025-03-13SELL-42 166.930* 179.79 Profit of 7,551 on sale
2025-03-11SELL-49 166.630* 180.03 Profit of 8,822 on sale
2025-03-10SELL-28 175.120* 180.09 Profit of 5,042 on sale
2025-03-06SELL-28 169.270* 180.25 Profit of 5,047 on sale
2025-03-05SELL-42 167.550* 180.40 Profit of 7,577 on sale
2025-03-04SELL-56 164.310* 180.58 Profit of 10,113 on sale
2025-02-28SELL-35 165.310* 180.96 Profit of 6,334 on sale
2025-02-26BUY14 167.960* 181.31
2025-02-24BUY14 170.510* 181.62
2025-02-21BUY7 163.020* 181.86
2025-02-20SELL-21 162.250* 182.10 Profit of 3,824 on sale
2025-02-14SELL-7 151.990* 183.50 Profit of 1,285 on sale
2025-02-13SELL-91 153.170* 183.91 Profit of 16,736 on sale
2025-02-12SELL-7 154.000* 184.32 Profit of 1,290 on sale
2025-02-06SELL-28 166.270* 185.66 Profit of 5,199 on sale
2025-02-05BUY7 165.870* 185.96
2025-02-04BUY49 163.120* 186.30
2025-01-29SELL-49 161.640* 187.75 Profit of 9,200 on sale
2025-01-28BUY14 163.640* 188.14
2025-01-24BUY7 164.970* 188.90
2025-01-22BUY14 168.220* 189.63
2025-01-16BUY14 165.800* 191.41
2025-01-15BUY7 173.910* 191.74
2025-01-10BUY14 186.120* 192.16
2025-01-02BUY21 182.640* 192.54
2024-12-31BUY14 184.600* 192.71
2024-12-27BUY7 186.160* 193.07
2024-12-20BUY21 185.770* 193.78
2024-12-19BUY7 182.150* 194.08
2024-12-18SELL-7 183.160* 194.36 Profit of 1,361 on sale
2024-12-17BUY14 189.330* 194.50
2024-12-13BUY7 190.460* 194.74
2024-12-10BUY7 197.050* 194.71
2024-12-06SELL-14 191.810* 194.57 Profit of 2,724 on sale
2024-12-05BUY7 191.540* 194.67
2024-12-04SELL-56 199.350* 194.51 Profit of 10,893 on sale
2024-12-03BUY21 199.300* 194.34
2024-12-02BUY35 201.250* 194.09
2024-11-27BUY7 199.590* 193.42
2024-11-26BUY49 197.750* 193.23
2024-11-21BUY21 194.190* 192.65
2024-11-20BUY14 187.900* 192.90
2024-11-19BUY7 186.100* 193.28
2024-11-18BUY14 187.500* 193.62
2024-11-12BUY28 215.940* 192.23
2024-11-11BUY14 220.690* 190.33
2024-11-08BUY56 215.390* 188.54
2024-11-07BUY49 210.290* 186.87
2024-11-06BUY56 214.200* 184.59
2024-11-05SELL-14 188.680* 184.22 Profit of 2,579 on sale
2024-11-04BUY14 182.480* 184.39
2024-11-01BUY49 180.960* 184.77
2024-10-28BUY35 186.520* 186.49
2024-10-25BUY77 182.120* 187.58
2024-10-23SELL-7 186.630* 190.49 Profit of 1,333 on sale
2024-10-21BUY7 195.040* 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of CRL

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-1998,1391131,07574.9%
2025-09-1862,9972121,43651.9%
2025-09-1792,1290727,00512.7%
2025-09-16115,39612317,67336.3%
2025-09-1566,3561151,09343.9%
2025-09-1277,5570176,81743.9%
2025-09-1187,9991204,23743.1%
2025-09-10122,6560398,56430.8%
2025-09-09125,4020471,64226.6%
2025-09-08178,3420414,72943.0%
2025-09-0576,2640192,66839.6%
2025-09-0494,7920179,53352.8%
2025-09-03139,6460216,26564.6%
2025-09-02112,81930183,91061.3%
2025-08-29105,9651,040180,20658.8%
2025-08-28183,9714248,97873.9%
2025-08-2771,8910134,03453.6%
2025-08-26109,85319166,15266.1%
2025-08-25147,16623300,78148.9%
2025-08-22251,1260414,08560.6%
2025-08-21102,1520149,37668.4%
2025-08-20152,7210215,94670.7%
2025-08-19118,8310172,88768.7%
2025-08-1893,0280164,64156.5%
2025-08-1596,5001180,16553.6%
2025-08-14147,9520251,45658.8%
2025-08-13820,20601,075,15376.3%
2025-08-12299,3220438,69968.2%
2025-08-11192,9170365,05852.8%
2025-08-0892,08966222,12841.5%
2025-08-07326,647522550,23059.4%
2025-08-06532,4347,827888,87359.9%
2025-08-05283,1486539,93852.4%
2025-08-04124,11154248,83449.9%
2025-08-01162,441300281,62257.7%
2025-07-31125,6480228,70654.9%
2025-07-30115,4870188,12161.4%
2025-07-29181,1590275,84365.7%
2025-07-28198,89649321,94161.8%
2025-07-25162,642111293,83155.4%
2025-07-24385,658456820,47247.0%
2025-07-23150,6500346,02043.5%
2025-07-22205,73626821,85325.0%
2025-07-21132,794101445,92029.8%
2025-07-1893,150207186,54249.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.